|
|
|
|
|
|
|
|
The Latest Research, Commentary, and News from Health Affairs
Wednesday, August 12, 2020
|
|
|
|
|
|
|
IN THE JOURNAL
RESEARCH ARTICLE: PHARMACEUTICALS & MEDICAL TECHNOLOGY
Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available
By Stacie B. Dusetzina, Juliette Cubanski, Leonce Nshuti, Sarah True, Jack Hoadley, Drew Roberts, and Tricia Neuman
Stacie Dusetzina and coauthors write: "Recent press reports and other evidence suggest that Medicare Part D plans may be encouraging the use of brand-name drugs instead of generics. However, the scope of such practices is unclear." To explore this question,
the authors examine brand-name and generic drug placements in Medicare formularies. Read More >>
|
|
|
|
|
A CLOSER LOOK—Vaccine-Preventable Diseases
In 2015 the cost of US adult vaccine avoidance was $8.95 billion. That year only 42 percent of US adults received the flu vaccine. Can a recovering economy handle such costs in the wake of COVID-19? How can we
increase access and prevent what is already preventable? Reread Sachiko Ozawa and coauthors' 2016 study in Health Affairs.
|
|
|
|
|
|
|
|
|
About Health Affairs
Health Affairs is the leading peer-reviewed journal at the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States
Privacy Policy
|
|
|
|
|
